American Society of Hematology, 2025 (ASH)7 - 9 December 2025
HIBISCUS 2 (Trial-in-Progress): A Global, Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults with Sickle Cell Disease
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.